Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
Academic Article
Publication Date:
2022
Short description:
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia / Sharman, J.P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J.M., Flinn, I.W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L.M., Herishanu, Y., Banerji, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., Cymbalista, F., et al.. - In: LEUKEMIA. - ISSN 0887-6924. - (2022). [10.1038/s41375-021-01485-x]
Iris type:
1.1 Articolo in rivista
List of contributors:
Sharman, J. P.; Egyed, M.; Jurczak, W.; Skarbnik, A.; Pagel, J. M.; Flinn, I. W.; Kamdar, M.; Munir, T.; Walewska, R.; Corbett, G.; Fogliatto, L. M.; Herishanu, Y.; Banerji, V.; Coutre, S.; Follows, G.; Walker, P.; Karlsson, K.; Ghia, P.; Janssens, A.; Cymbalista, F.; Woyach, J. A.; Ferrant, E.; Wierda, W. G.; Munugalavadla, V.; Yu, T.; Wang, M. H.; Byrd, J. C.
Published in: